Antibacterial Prodrugs
2024
Raivis Žalubovskis

Bacterial resistance against antibiotics is a growing threat to the society. Various approaches are used for the development of new resistance-free antibiotics. As an important and growing field is antibacterial prodrugs. Prodrugs, being inactive against bacteria, undergo chemical modification or activation within target bacteria to release the active form of the drug. In this chapter, we summarize common strategies for the development of antibacterial prodrugs including β-lactamase-activated prodrugs, Cephalosporin-3′-diazeniumdiolate prodrugs, glycoside-based prodrugs, pyrimidine nucleoside derivative prodrugs, Carvacrol prodrugs, and antimicrobial peptides-based prodrugs. Short clinical and preclinical advances are highlighted.


Keywords
Active drug | Antibacterials | Bacterial resistance | Prodrug
DOI
10.1016/B978-0-443-15635-9.00017-1
Hyperlink
https://www.sciencedirect.com/science/article/abs/pii/B9780443156359000171?via%3Dihub

Žalubovskis, R. Antibacterial Prodrugs. In: Advances in Prodrugs: Design and Therapeutic Applications. Amsterdam: Elsevier, 2024. pp.317-328. ISBN 978-0-443-15635-9. Available from: doi:10.1016/B978-0-443-15635-9.00017-1

Publication language
English (en)
The Scientific Library of the Riga Technical University.
E-mail: uzzinas@rtu.lv; Phone: +371 28399196